Cerevel Therapeutics Holdings Inc

Cerevel Therapeutics Holdings, Inc. engages in the discovery and development of new therapies for neuroscience diseases. The firm's portfolio focuses on diseases such as schizophrenia, epilepsy, and Parkinson's disease. Its product candidates include CVL-231, Darigabat, Tavapadon, CVL-871, and CVL-936. The company was founded in 2018 and is headquartered in Cambridge, MA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q2 2024

Earnings data Q3 2024

Cerevel Therapeutics reports successful 2022, eyes transformative neuroscience advancements

Cerevel Therapeutics had a productive year, focusing on transformative neuroscience.
Strong financial position with cash resources to fund operations into 2025.
Facing challenges with trial delays but addressing them with mitigation plans.
Opportunities lie in upcoming data readouts and exploring new indications.

Cerevel Therapeutics reports strong financials, navigates trial challenges for growth

Cerevel Therapeutics is well-positioned financially with a focus on operational efficiency and trial success, supported by strong cash reserves.
The company faces challenges in pipeline management and trial enrollment dynamics, necessitating strategic adjustments and careful oversight.
Opportunities lie in external growth initiatives, potential product approvals, and expanding therapeutic reach through strategic trial designs.

Cerevel Therapeutics advances key programs amidst challenges, eyes growth opportunities

Cerevel Therapeutics is making progress in key programs, leveraging its strong balance sheet and commitment to patients. Challenges in trial delays and patient selection criteria persist, but the company's focus on quality data and financial strength bode well for future growth.

Cerevel Therapeutics excels in Q3 with robust pipeline and financials

Cerevel Therapeutics demonstrated robust performance in Q3 2023, driven by a strong pipeline and solid financial foundation.
While facing challenges like high rollover rates and data disclosure timelines, the company is well-positioned to capitalize on transformative opportunities.
Strategic focus on quality, innovation, and market expansion underscores Cerevel's commitment to advancing novel therapies for neurological disorders.
With key data readouts expected in 2024 and a clear roadmap for regulatory filings, Cerevel is poised for significant growth and impact in the neurology space.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Emraclidine now the international nonproprietary name (INN) for CVL-231, an M4-selective positive allosteric modulator in development for schizophrenia

Cerevel Therapeutics to Present at 40th Annual JP Morgan Healthcare Conference: Additional Details of Phase 2 Program for Emraclidine (CVL-231) in Schizophrenia to be Presented

CAMBRIDGE, Mass., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a global company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced that Chairperson and Chief Executive Officer Tony Coles, M.D., will present at the upcoming virtual 40th Annual J.P. Morgan Healthcare Conference. Dr. Coles will be joined by Chief Medical Officer Raymond Sanchez, M.D., and Chief Scientific Officer John Renger, Ph.D., for the question-and-answer portion of the presentation.

Cerevel to Present at the 40th Annual J.P. Morgan Healthcare Conference

Companies will utilize cutting-edge brain organoids and advanced multi-modal “deep phenotyping” approach designed to enable the development of therapies with the potential to improve and reverse symptoms of schizophrenia Companies will utilize cutting-edge brain organoids and advanced multi-modal “deep phenotyping” approach designed to enable the development of therapies with the potential to improve and reverse symptoms of schizophrenia

Cerevel Therapeutics and Herophilus Announce Collaboration to Evaluate Novel Neuroimmune Modulating Therapeutic Strategies for Schizophrenia

Cerevel Therapeutics Holdings, Inc. (CERE) CEO Tony Coles on Q3 2021 Results - Earnings Call Transcript

Phase 1 data for darigabat in acute anxiety now expected by the end of Q1 2022

Cerevel Therapeutics Reports Third Quarter 2021 Financial Results and Pipeline Updates

CAMBRIDGE, Mass., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced that it will participate in four upcoming virtual investor conferences during the months of November and December.

Cerevel Therapeutics to Participate at Upcoming Virtual Investor Conferences

CAMBRIDGE, Mass., Oct. 20, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it will report third quarter 2021 financial results and pipeline updates on Wednesday, November 10, 2021, before the U.S. financial markets open.

Cerevel Therapeutics to Report Third Quarter 2021 Financial Results on Wednesday, November 10, 2021

Live webcast today from 10:00 to 11:30 a.m. ET

Cerevel Therapeutics Hosts Virtual R&D Event to Review CVL-871 in Dementia-Related Apathy and Provide Update on CVL-231 for the Treatment of Schizophrenia

Current Chief Accounting Officer Mark Bodenrader named as interim CFO

Cerevel Therapeutics Announces Departure of CFO Kathy Yi

New York, New York--(Newsfile Corp. - September 15, 2021) - Levi & Korsinsky announces it has commenced an investigation of Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) concerning possible breaches of fiduciary duty. To obtain additional information, go to:https://www.zlk.com/compensation2/cerevel-therapeutics-holdings-inc-information-request-form or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500. There is no cost or obligation to you.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Cerevel Therapeutics Holdings, Inc. - CERE

Event will focus on CVL-871, a D1/D5 partial agonist in development for dementia-related apathy, and will include an update on CVL-231, an M4 positive allosteric modulator for the treatment of schizophrenia

Cerevel Therapeutics to Host Virtual R&D Event on October 7

Adagio Therapeutics

Bicycle Therapeutics Plc - ADR

Find out what these industry favorites are doing to impress investors.

3 Biotech Stocks That Soared to New Heights Last Week

Virtus LifeSci Biotech Clinical Trials ETF

BioNTech SE

CM Life Sciences II Inc - Unit

Loncar Cancer Immunotherapy ETF

iShares Evolved U.S. Innovative Healthcare ETF

Pfizer

Reflecting what it considers the vast potential of life sciences companies, Bain Capital is making another huge bet on the industry. The Boston-based investment firm has raised $1.9 billion in a new fund directed at pharmaceutical, biotechnology and medical device companies, reported Endpoints News.

Should Investors Follow Private Equity into Life Sciences?

Cerevel Therapeutics Holdings, Inc. (CERE) CEO Tony Coles on Q2 2021 Results - Earnings Call Transcript

Announced positive topline results for CVL-231 in Phase 1b trial in schizophrenia

Cerevel Therapeutics Reports Second Quarter 2021 Financial Results and Business Updates

New York, New York--(Newsfile Corp. - August 2, 2021) - Levi & Korsinsky announces it has commenced an investigation of Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) concerning possible breaches of fiduciary duty. To obtain additional information, go to:https://www.zlk.com/compensation2/cerevel-therapeutics-holdings-inc-information-request-form or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500. There is no cost or obligation to you.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Cerevel Therapeutics Holdings, Inc. - CERE

CAMBRIDGE, Mass., July 30, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE; CEREW) (the “Company”), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced that on August 30, 2021 at 5:00 p.m. ET, it will redeem all of its outstanding public warrants to purchase shares of the Company's common stock that were issued under the Warrant Agreement, dated as of June 9, 2020, by and between the Company (f/k/a ARYA Sciences Acquisition Corp II) and Continental Stock Transfer & Trust Company (“Continental”), as warrant agent.

Cerevel Therapeutics Announces Redemption of Public Warrants

CAMBRIDGE, Mass., July 22, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it will report second quarter 2021 financial results and provide a pipeline update on Wednesday, August 11, 2021, before the U.S. financial markets open.

Cerevel Therapeutics to Report Second Quarter 2021 Financial Results on Wednesday, August 11, 2021

A positive early stage trial for a schizophrenia drug has pushed this biotech's stock this year.

Why Cerevel Therapeutics Is Up More Than 29% in the First Half of 2021

A10 Networks

Hibbett Sports

Integer Holdings

Increased analyst coverage over the past few weeks might lead to solid price appreciation for stocks like HIBB, ITGR, CERE and ATEN.

New Analyst Coverage Puts Spotlight on These 4 Stocks

Investors aren't thrilled about how this biotech intends to pay operating expenses that are about to balloon.

Here's What's Pushing Cerevel Therapeutics Stock Lower Today

CAMBRIDGE, Mass., July 01, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced today the pricing of its previously announced underwritten public offering of 14,000,000 shares of common stock at a public offering price of $25.00 per share. The gross proceeds to Cerevel of the offering, before deducting underwriting discounts and commissions and other estimated offering expenses, are expected to be approximately $350 million. The offering is expected to close on July 7, 2021, subject to customary closing conditions. In addition, Cerevel has granted the underwriters a 30-day option to purchase an additional 2,100,000 shares of its common stock, at the public offering price, less underwriting discounts and commissions.

Cerevel Therapeutics Announces Pricing of $350 Million Public Offering of Common Stock

Cerevel Therapeutics (CERE) surges as schizophrenia candidate, CVL-231, demonstrates clinically meaningful and statistically significant improvement in PANSS Total score at 6 weeks in phase Ia study.

Cerevel (CERE) Novel Schizophrenia Drug Succeeds in Phase I

Cerevel Therapeutics is taking on schizophrenia with its newest drug treatment. After posting positive trial results, CERE stock is up big.

CERE Stock: The Huge News That Has Cerevel Therapeutics Skyrocketing

Sensei Biotherapeutics

You might not have heard of them, but one went up big while the other served up a massive disappointment.

News for Cerevel Therapeutics Holdings Inc Stock (CERE)